Get the Stockscreener App
1.15
1.77%
0.02
Pre-market:
1.17
0.02
+1.74%
Applied Therapeutics Inc stock is traded at $1.15, with a volume of 1.62M.
It is up +1.77% in the last 24 hours and up +90.11% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$1.13
Open:
$1.11
24h Volume:
1.62M
Relative Volume:
0.35
Market Cap:
$165.61M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.8519
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
-16.06%
1M Performance:
+90.11%
6M Performance:
+181.04%
1Y Performance:
-86.99%
1-Day Range:
$1.0902
$1.24
1-Week Range:
$1.08
$1.39
52-Week Range:
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
1.15 | 162.73M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
News impact scoring models applied to Applied Therapeutics Inc.July 2025 Reactions & Safe Capital Growth Tips - newser.com
Statistical indicators supporting Applied Therapeutics Inc.’s strength2025 Technical Overview & Accurate Entry and Exit Point Alerts - newser.com
Does Applied Therapeutics Inc. show high probability of rebound2025 EndofYear Setup & Risk Managed Investment Signals - newser.com
How geopolitical tensions affect Applied Therapeutics Inc. stockQuarterly Profit Review & Real-Time Buy Signal Notifications - newser.com
Is Applied Therapeutics Inc. (2UV) stock among top earnings playsEarnings Growth Summary & Long-Term Safe Investment Plans - newser.com
Applying big data sentiment scoring on Applied Therapeutics Inc.Rate Cut & High Return Trade Opportunity Guides - newser.com
Is Applied Therapeutics Inc. stock a good choice for value investorsMarket Performance Recap & Weekly Return Optimization Alerts - newser.com
What makes Applied Therapeutics Inc. stock attractive to growth fundsJuly 2025 PostEarnings & Free Weekly Chart Analysis and Trade Guides - newser.com
Are Analysts Too Optimistic About Bajaj Consumer Care Limiteds Revenue GrowthMarket Breadth Indicators & Low Cost Trading Plans - earlytimes.in
What data driven models say about Applied Therapeutics Inc.’s futureMarket Growth Summary & Real-Time Volume Analysis - newser.com
Why Applied Therapeutics Inc. (2UV) stock is a must watch tickerPortfolio Value Summary & Long-Term Growth Plans - newser.com
Analyzing Applied Therapeutics Inc. with multi timeframe chartsWeekly Investment Report & Verified Short-Term Trading Plans - newser.com
Can Applied Therapeutics Inc. (2UV) stock surprise markets with earningsPortfolio Gains Report & Comprehensive Market Scan Reports - newser.com
What does recent volatility data suggest for Applied Therapeutics Inc.Entry Point & Short-Term Trading Opportunity Alerts - newser.com
Can Applied Therapeutics Inc. (2UV) stock double in coming yearsJuly 2025 Market Mood & Reliable Entry Point Alerts - newser.com
Custom watchlist performance reports with Applied Therapeutics Inc.Weekly Profit Report & Growth Focused Entry Reports - newser.com
Applied Therapeutics (APLT) Projected to Post Earnings on Thursday - MarketBeat
Volume spikes in Applied Therapeutics Inc. stock – what they meanJuly 2025 Rallies & Verified Entry Point Detection - newser.com
What makes IVCAW stock price move sharply - newser.com
Developing predictive dashboards with Applied Therapeutics Inc. dataTrade Exit Summary & Technical Confirmation Trade Alerts - newser.com
Can Applied Therapeutics Inc. (2UV) stock ride next bull market cycleWeekly Trade Review & Trade Opportunity Analysis Reports - newser.com
Published on: 2025-10-30 23:56:28 - newser.com
Published on: 2025-10-30 05:47:01 - newser.com
Real time alert setup for Applied Therapeutics Inc. performanceJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Why Applied Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Earnings & Safe Investment Capital Preservation Plans - fcp.pa.gov.br
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):